MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 529012 | Name: Levonadifloxacin free base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levonadifloxacin is a broad-spectrum fluoroquinolone antibiotic potentially for the treatment of staphylococci.

Chemical Structure

Levonadifloxacin free base
CAS#154357-42-3 (free base)

Theoretical Analysis

MedKoo Cat#: 529012

Name: Levonadifloxacin free base

CAS#: 154357-42-3 (free base)

Chemical Formula: C19H21FN2O4

Exact Mass: 360.1485

Molecular Weight: 360.39

Elemental Analysis: C, 63.32; H, 5.87; F, 5.27; N, 7.77; O, 17.76

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
10mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
154357-42-3 (free base) 627891-34-3 (arginine hydrate) 306748-89-0 (arginine)
Synonym
WCK-771A; WCK-771; WCK771A; WCK771; WCK 771A; WCK 771; Levonadifloxacin free base;
IUPAC/Chemical Name
(S)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid
InChi Key
JYJTVFIEFKZWCJ-JTQLQIEISA-N
InChi Code
InChI=1S/C19H21FN2O4/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21/h8-11,23H,2-7H2,1H3,(H,25,26)/t10-/m0/s1
SMILES Code
O=C(C1=CN2C3=C(C=C(F)C(N4CCC(O)CC4)=C3CC[C@@H]2C)C1=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent.
In vitro activity:
Levonadifloxacin demonstrated potent activity against MRSA, QRSA, and MR-CoNS strains with significantly lower minimum inhibitory concentration MIC 50/90 values of 0.5/1 mg/L as compared with levofloxacin (8/32 mg/L) and moxifloxacin (2/8 mg/L). Reference: J Lab Physicians. 2020 Dec;12(3):230-232. https://pubmed.ncbi.nlm.nih.gov/33268943/
In vivo activity:
Fluoroquinolones are reported to possess immunomodulatory activity; hence, a novel benzoquinolizine fluoroquinolone, levonadifloxacin, was evaluated in lipopolysaccharide-stimulated human whole-blood (HWB) and mouse acute lung injury (ALI) models. Levonadifloxacin significantly mitigated the inflammatory responses in an HWB assay through inhibition of proinflammatory cytokines and in the ALI model by lowering lung total white blood cell count, myeloperoxidase, and cytokine levels. Reference: Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00084-20. https://pubmed.ncbi.nlm.nih.gov/32152077/
Solvent mg/mL mM comments
Solubility
DMSO 125.0 346.85
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 360.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Mamtora D, Saseedharan S, Rampal R, Joshi P, Bhalekar P, Ahdal J, Jain R. In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital. J Lab Physicians. 2020 Dec;12(3):230-232. doi: 10.1055/s-0040-1720944. Epub 2020 Nov 23. PMID: 33268943; PMCID: PMC7684988. 2. Baliga S, Mamtora DK, Gupta V, Shanmugam P, Biswas S, Mukherjee DN, Shenoy S. Assessment of antibacterial activity of levonadifloxacin against contemporary gram-positive clinical isolates collected from various Indian hospitals using disk-diffusion assay. Indian J Med Microbiol. 2020 Jul-Dec;38(3 & 4):307-312. doi: 10.4103/ijmm.IJMM_20_307. PMID: 33154240. 3. Patel A, Sangle GV, Trivedi J, Shengule SA, Thorve D, Patil M, Deshmukh NJ, Choudhari B, Karade A, Gupta S, Bhagwat S, Patel M. Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00084-20. doi: 10.1128/AAC.00084-20. PMID: 32152077; PMCID: PMC7179645. 4. Bhagwat SS, Periasamy H, Takalkar SS, Chavan R, Tayde P, Kulkarni A, Satav J, Zope V, Patel M. In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00909-19. doi: 10.1128/AAC.00909-19. PMID: 31208999; PMCID: PMC6658750.
In vitro protocol:
1. Mamtora D, Saseedharan S, Rampal R, Joshi P, Bhalekar P, Ahdal J, Jain R. In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital. J Lab Physicians. 2020 Dec;12(3):230-232. doi: 10.1055/s-0040-1720944. Epub 2020 Nov 23. PMID: 33268943; PMCID: PMC7684988. 2. Baliga S, Mamtora DK, Gupta V, Shanmugam P, Biswas S, Mukherjee DN, Shenoy S. Assessment of antibacterial activity of levonadifloxacin against contemporary gram-positive clinical isolates collected from various Indian hospitals using disk-diffusion assay. Indian J Med Microbiol. 2020 Jul-Dec;38(3 & 4):307-312. doi: 10.4103/ijmm.IJMM_20_307. PMID: 33154240.
In vivo protocol:
1. Patel A, Sangle GV, Trivedi J, Shengule SA, Thorve D, Patil M, Deshmukh NJ, Choudhari B, Karade A, Gupta S, Bhagwat S, Patel M. Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00084-20. doi: 10.1128/AAC.00084-20. PMID: 32152077; PMCID: PMC7179645. 2. Bhagwat SS, Periasamy H, Takalkar SS, Chavan R, Tayde P, Kulkarni A, Satav J, Zope V, Patel M. In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00909-19. doi: 10.1128/AAC.00909-19. PMID: 31208999; PMCID: PMC6658750.
1: Bhagwat SS, Mundkur LA, Gupte SV, Patel MV, Khorakiwala HF. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob Agents Chemother. 2006 Nov;50(11):3568-79. PubMed PMID: 16940059; PubMed Central PMCID: PMC1635177. 2: Appelbaum PC, Pankuch GA, Bozdogan B, Lin G, Jacobs MR, Patel MV, Gupte SV, Jafri MA, De Souza NJ, Khorakiwala HF. Activity of the new quinolone WCK 771 against pneumococci. Clin Microbiol Infect. 2005 Jan;11(1):9-14. PubMed PMID: 15649298. 3: Patel MV, De Souza NJ, Gupte SV, Jafri MA, Bhagwat SS, Chugh Y, Khorakiwala HF, Jacobs MR, Appelbaum PC. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother. 2004 Dec;48(12):4754-61. PubMed PMID: 15561853; PubMed Central PMCID: PMC529196. 4: Jacobs MR, Bajaksouzian S, Windau A, Appelbaum PC, Patel MV, Gupte SV, Bhagwat SS, De Souza NJ, Khorakiwala HF. In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob Agents Chemother. 2004 Sep;48(9):3338-42. PubMed PMID: 15328094; PubMed Central PMCID: PMC514757. 5: Yeole RD, Jadhav AS, Patil KR, Rane VP, Kubal ML, Singh S, Patel MV, Khorakiwala HF. Validated chiral high-performance liquid chromatography method for a novel anti-methicillin-resistant Staphylococcus aureus fluoroquinolone WCK 771. J Chromatogr A. 2006 Mar 3;1108(1):38-42. PubMed PMID: 16426621. 6: Yeole RD, Kulkarni VL, Latad SB, Chavan RP, Chugh Y, Patel MV, Khorakiwala HF. Simple liquid chromatography-tandem mass spectrometry method for determination of novel anti-methicillin-resistant Staphylococcus aureus fluoroquinolone WCK 771 in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):306-12. PubMed PMID: 17027349. 7: Bhagwat SS, McGhee P, Kosowska-Shick K, Patel MV, Appelbaum PC. In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types. Antimicrob Agents Chemother. 2009 Feb;53(2):811-3. doi: 10.1128/AAC.01150-08. Erratum in: Antimicrob Agents Chemother. 2009 Mar;53(3):1298. PubMed PMID: 19029326; PubMed Central PMCID: PMC2630593. 8: Al-Lahham A, De Souza NJ, Patel M, René Reinert R. Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes. J Antimicrob Chemother. 2005 Dec;56(6):1130-3. PubMed PMID: 16239291. 9: Peric M, Jacobs MR, Appelbaum PC. Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. Antimicrob Agents Chemother. 2004 Aug;48(8):3188-92. PubMed PMID: 15273148; PubMed Central PMCID: PMC478502. 10: Jacobs MR, Appelbaum PC. Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother. 2006 Oct;7(14):1957-66. Review. PubMed PMID: 17020421. 11: Appelbaum PC, Jacobs MR. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol. 2005 Oct;8(5):510-7. Review. PubMed PMID: 16098786. 12: Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother. 2003 Nov;52(5):864-8. PubMed PMID: 14563898.